[Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]

Bosshard, Piet; Roth, Beat (2019). [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]. Revue médicale suisse, 15(673), pp. 2190-2194. Médecine & Hygiène

Text Ro_Chimiotherapie neoadjuvante a base.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (256kB)

For more than 30 years, cisplatin-based neoadjuvant chemotherapy (NAC) has been administered to patients with muscle-invasive bladder cancer (MIBC). However, the benefit is modest. With the advent of modern immunotherapies, new therapeutic strategies are also opening up to bladder cancer. Unfortunately, the initial results in the neoadjuvant context show a response rate of only 20-35 %. Other therapeutic strategies, such as Pan-FGFR inhibitors, do not show better response. Due to the high genetic variability of bladder cancer, a « one drug fits all » concept is not an ideal solution. Patient selection based on the probability of response appears to be a promising strategy to improve this modest benefit of each treatment. In this context, the NAC will also continue to play an important role.

Interest & Impact

Downloads

6 since deposited on 03 Feb 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item